February is heart health month — but heart disease is a year-round fight.
In the United States, February is about more than Valentine’s Day hearts. It’s a time to promote awareness of Heart Disease. Many of your patients likely think they’re too young to worry about heart disease but the fact is the lifestyle choices they make today affect their risk for cardiovascular diseases in the future.
Heart disease can affect anyone.
While the mortality rates around CVD are grim, the good news is at least 80% of premature deaths from heart disease and stroke can be avoided.1 That’s because CVD is often triggered by lifestyle factors you can help your patients control, such as hypertension, smoking, obesity, poor diet, and alcohol abuse. Any one of these risk factors can double your patients’ risk of contracting cardiovascular disease — and it’s estimated that about half of all adults have at least one risk factor.2
Early detection is essential to cardiac care.
Whether you have a patient who has cardiovascular disease — or is at high risk for developing it due to an underlying condition like hypertension, diabetes, hyperlipidaemia or cardiac conditions — early detection and management can make all the difference.
At Abbott, we’re committed to the early diagnosis of cardiovascular disease. Our comprehensive solutions are a natural fit for a wide range of outpatient settings — including physician offices, clinics, community health centers, hospitals and long-term care facilities, emergency rooms, and hospital outpatient clinics.
Accurate, actionable results from the leader in point-of-care lipid testing.
The CLIA-waived Alere Cholestech LDX® System helps identify and monitor your at-risk patients. Engineered for confidence, this analyzer provides accurate, actionable, and readily accessible results for point-of-care lipid profile, cholesterol, and glucose testing in minutes. As a result, you can provide counseling about improving lifestyle habits and minimizing risk factors — as well as prescribing medication, if appropriate — all in the same appointment.
Improve the way you diagnose, monitor and manage patients.
Diabetes, chronic kidney disease and heart disease are a set of chronic conditions that sadly go hand in hand. The Afinion™ analyzer provides immediate results to monitor diabetes and assess the comorbidity of chronic kidney disease.
The Afinion™ HbA1c assay is a CLIA-waived test for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, used to monitor metabolic control in patients with diabetes. It provides test results in three minutes for improved diabetic control, better patient outcomes, and enhanced clinic efficiencies. The Afinion™ ACR provides quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine, used for early identification of renal disease in patients with diabetes and/or hypertension. The Afinion™ ACR test results are ready in just five minutes.
Fast. Reliable. Accurate.
The i-STAT System is an advanced, portable and easy-to-use handheld blood analyzer that provides healthcare professionals with real-time, lab-quality results in minutes — not hours. Obtaining accurate results within minutes allows healthcare professionals to accelerate decision-making and treatment. The i-STAT System offers a broad menu of clinical tests, including cardiac markers, coagulation, lactate, blood gases, and electrolytes.
Patients whose cardiac conditions result in acute myocardial infarction need rapid responsive care to improve patient outcomes. Rapid point-of-care troponin testing may increase the overall quality of care and drive timely treatment for patients experiencing an acute coronary syndrome (ACS). Incorporating point-of-care serial troponin testing into standardized order sets and protocols for suspected ACS patients could lead to improved diagnostic accuracy for patients presenting with suspected acute MI.7,8